SEC Comment Letter 0000000000-22-014003 to Arcturus Therapeutics Holdings Inc. (ARCT) (CIK 0001768224) (ARCT)
Arcturus Therapeutics Holdings Inc. (ARCT) (CIK 0001768224)
Date: Dec. 29, 2022 · CIK: 0001768224 · Accession: 0000000000-22-014003
AI Filing Summary & Sentiment
File numbers found in text: 333-269003
Letter
United States securities and exchange commission logo December 29, 2022 Joseph E. Payne Chief Executive Officer Arcturus Therapeutics Holdings Inc. 10628 Science Center Drive, Suite 250 San Diego, California 92121 Re:Arcturus Therapeutics Holdings Inc. Registration Statement on Form S-3 Filed December 23, 2022 File No. 333-269003 Dear Joseph E. Payne: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jeffrey Baumel, Esq.
Show Raw Text
United States securities and exchange commission logo
December 29, 2022
Joseph E. Payne
Chief Executive Officer
Arcturus Therapeutics Holdings Inc.
10628 Science Center Drive, Suite 250
San Diego, California 92121
Re:Arcturus Therapeutics Holdings Inc.
Registration Statement on Form S-3
Filed December 23, 2022
File No. 333-269003
Dear Joseph E. Payne:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jeffrey Baumel, Esq.